Merck Gets FDA Expanded OK for Keytruda in Breast Cancer
July 27 2021 - 7:00AM
Dow Jones News
By Colin Kellaher
Merck & Co. on Tuesday said the U.S. Food and Drug
Administration approved the expanded use of its blockbuster cancer
drug Keytruda in an aggressive type of breast cancer that has an
increased risk for recurrence.
The Kenilworth, N.J., drugmaker said the approval covers
Keytruda for the treatment of patients with high-risk, early-stage
triple-negative breast cancer in combination with chemotherapy as
neoadjuvant treatment and then continued as a single agent as
adjuvant treatment after surgery.
Merck said Keytruda, a cancer drug that harnesses a patient's
immune system to fight tumors, is now approved for 30 indications
in the U.S.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 27, 2021 06:59 ET (10:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
